Overview of High Tide Inc.’s Recent Performance

High Tide Inc. (TSX: HITI) reported a record‑setting second‑quarter (Q2) 2026 financial performance. Revenue rose to $179.3 million CAD, a 30 % increase from the $137.8 million CAD reported for the same quarter in 2025. Adjusted EBITDA for the period reached $13.9 million CAD.

The company’s earnings call, held on June 16, 2026, highlighted:

  • Improved gross and operating margins driven by higher sales volumes and disciplined cost management.
  • A strategic expansion of the Canna Cabana loyalty program, which is expected to drive repeat retail sales.
  • Continued growth of its German subsidiary, Remexian Pharma, which showcased exclusive Canadian medical‑cannabis brand partnerships at the Mary Jane Berlin 2026 event, reinforcing High Tide’s position in the international medical‑cannabis market.

Market Reaction

Shares of High Tide Inc. surged 15.1 % in pre‑market trading on June 16, 2026, and closed at $2.25 CAD on the prior trading day (June 15). The market reaction reflected investor confidence in the company’s revenue growth and its expanding presence both in Canada and abroad.

Capital Allocation

On June 15, 2026, High Tide announced the approval of a $40 million CAD capital‑expenditure facility to support its growth initiatives. The same day the company also confirmed an acquisition of Northern Helm dispensaries, a move that will expand its retail footprint in key Canadian markets.

Financial Position

  • Market Capitalisation: $279.5 million CAD
  • Price‑to‑Earnings Ratio: –5.78 (negative earnings per share for the quarter)
  • 52‑Week High/Low: $5.59 / $2.94 CAD
  • Close Price (June 16): $3.34 CAD

The negative P/E ratio indicates that earnings per share were below zero for the quarter, which is typical for a high‑growth company investing heavily in expansion.

Outlook

High Tide’s management indicated that the company will continue to:

  1. Expand its Canna Cabana loyalty program to increase customer retention.
  2. Leverage Remexian Pharma’s partnerships in Europe to enter new medical‑cannabis markets.
  3. Deploy the newly approved capital‑expenditure facility to open additional dispensaries and invest in supply‑chain efficiencies.

These initiatives are expected to sustain the upward revenue trajectory and improve profitability in subsequent quarters.